Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.58 USD | -0.52% | -1.15% | -20.28% |
07/05 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
02/05 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.28% | 80.95B | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89